Skip to content
Screener

Allogene Therapeutics ALLO Q2 2026 earnings

Reported August 12, 2026 · After market close

Revenue$4.6MBeat by $4.6M
EPS-$0.13Beat by $0.04
Revenue estimate$2.5K
EPS estimate-$0.17

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q2 2026

Income statement

See full
Revenue$4.6M—
Operating income-$46.9M+17.4%
Net income-$42.7M+16.2%
EPS (diluted)-$0.13+43.5%

Balance sheet

See full
Cash & equivalents$48.9M-21.9%
Total debt$79.0M-9.2%
Total equity$436.2M+26.6%
Total assets$550.1M+16.9%

Cash flow

See full
Operating cash flow-$32.0M+18.0%
CapEx$150.0K+241%
Free cash flow-$32.1M+17.7%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$704.8M+174%
Enterprise value$734.89M+161%
P/S151.9×—

Returns & leverage

See full
Return on equity-42.4%-8.0pp
Debt / equity0.2×-0.1×
Current ratio10.7×+1.8×

Segments

By segment

See full
Reportable Segment$4.6M—

Versus estimates

Revenue

Q2 2026$4.6MBeat by $4.6M

Diluted EPS

Q2 2026-$0.13Beat by $0.04
Q1 2026-$0.18Beat by $0.01Q4 2025-$0.17Beat by $0.08Q3 2025-$0.19Beat by $0.04Q2 2025-$0.23Beat by $0.05Q1 2025-$0.28In line

FAQ

When did Allogene Therapeutics report Q2 2026 earnings?
Allogene Therapeutics (ALLO) reported Q2 2026 earnings on August 12, 2026 after market close.
What were Allogene Therapeutics's Q2 2026 revenue and EPS?
Allogene Therapeutics reported revenue of $4.6M and eps of $-0.13 for Q2 2026.
Did Allogene Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $2.5K by $4.6M. EPS beat the consensus estimate of $-0.17 by $0.04.
How did Allogene Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 43.5% from $-0.23.
Where can I find Allogene Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-056198) and the 10-Q periodic report (0001628280-26-056213) directly on SEC EDGAR. The filing index links above go to sec.gov.